Our Science – Price Website
Douglas K. Price, Ph.D.
Selected Publications |
 |
| 1)
Price DK, Ayres JA, Pasqualone D, Cabell CH, Miller W, Hardison RC. The 5' ends of LINE1 repeats in rabbit DNA define subfamilies and reveal a short sequence conserved between rabbits and humans. Genomics. 14: 320-31, 1992. [Journal] |
|
| 2)
Price DK, Woodard W, Teigland CM. Simultaneous detection of circulating prostate-specific antigen (PSA)-expressing and prostate-specific membrane (PSM)-expressing cells by a multiplex reverse transcriptase polymerase chain reaction (RT-PCR) assay. Urologic Oncology. 1: 226-233, 1995. [Journal] |
|
| 3)
Price DK, Zhang F, Ashley CT, Warren ST. The chicken FMR1 gene is highly conserved with a CCT 5'-untranslated repeat and encodes an RNA-binding protein. Genomics. 31: 3-12, 1996. [Journal] |
|
| 4)
Price DK, Clontz DR, Woodard WL, Kaufman JS, Daniels JM, Stolzenberg SJ, Teigland CM. Detection and clearance of prostate cells subsequent to ultrasound-guided needle biopsy as determined by multiplex nested reverse transcription polymerase chain reaction assay. Urology. 52: 261-6; discussion 266-7, 1998. [Journal] |
|
| 5)
Montgomery JS, Price DK, Figg WD. The androgen receptor gene and its influence on the development and progression of prostate cancer. J. Pathol. 195: 138-46, 2001. [Journal] |
|
| 6)
Price DK, Ando Y, Kruger EA, Weiss M, Figg WD. 5'-OH-thalidomide, a metabolite of thalidomide, inhibits angiogenesis. Therapeutic drug monitoring. 24: 104-10, 2002. [Journal] |
|
| 7)
Sissung TM, Price DK, Sparreboom A, Figg WD. Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention. Mol. Cancer Res. 4: 135-50, 2006. [Journal] |
|
| 8)
Li H, Price DK, Figg WD. ADH1, an N-cadherin inhibitor, evaluated in preclinical models of angiogenesis and androgen-independent prostate cancer. Anticancer Drugs. 18: 563-8, 2007. [Journal] |
|
| 9)
Kristal AR, Price DK, Till C, Schenk JM, Neuhouser ML, Ockers S, Lin DW, Thompson IM, Figg WD. Androgen receptor CAG repeat length is not associated with the risk of incident symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. Prostate. 70: 584-90, 2010. [Journal] |
|
| 10)
Deeken JF, Cormier T, Price DK, Sissung TM, Steinberg SM, Tran K, Liewehr DJ, Dahut WL, Miao X, Figg WD. A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform. The pharmacogenomics journal. 2009. [Journal] |
|
| Click Here to View Expanded Bibliography. |
This page was last updated on 4/30/2010.
